Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SHURTHA
Zero, I repeat, ZERO gaurantee we get a PR
Its possible, but DO NOT BET ON IT
Cheers!
Just Bought 21k
Go CVM
I love this ticker!
Cheers
I Might Look at Adding Today For Another Swing
Looks like it has bottomed for now
CHeers!
Why did Michael Bigger tweet “Flaskworks” this morning?
That’s the entire tweet.
FlaskWorks
— Michael Bigger (@biggercapital) April 20, 2022
@Shurtha
Wait for the $2s
New baggies are going to get frustrated and start selling at these levels.
$2.90 is my buy zone
THIS IS HOW YOU TRADE THIS STOCK!
Cheers!
Woof!
Falling KNIFE!
$2s....
Come to daddy
Cheers!
Too Funny
This stock is a money maker for me.
Its the gift the keeps on giving!
Waiting for $2s for another swing. Made $36K yesterday!
Cheers
You seem upset
Cheers
@q
Too funny. Fantasy world is my favorite place in Disney too
I do hope u were smart and sold some shares yesterday. What a lost opportunity if you didn’t. That’s what smart people did.
Back to square one here. LOL
I’m seeing a dip into the $2s today
Cheers!
What a gift today was. That’s why you always have swing shares!
Gonna buy back in tomorrow. I’ll wait for the dip first
Cheers
Too funny. He “baited” him?
Confirmation bias in full strength
Cheers
All in a tax deffered Roth acct
Wow. I’m $36k richer than when I went to bed.
So glad I bought and sold today.
Cheers.
Correction. $5.24.
Sold all my shares . $6.24. made about 36K I’ll be looking to buy back in later today cheers
HALTED
BOOM!
Bought 18K this morning!
Daddy is sooo happy and so is annette
RV coming sooner!
GO CVM
I LOVE CVM
Cheers!
HERE IS THE STAT ARTICLE BY FEARSTAIN
Geert Kersten, the CEO of drugmaker Cel-Sci, stopped communicating publicly soon after the company’s cancer drug failed to prolong the survival of patients in a large clinical trial last June. Privately, Kersten is talking to select investors. And what he’s telling them could land him and Cel-Sci in trouble with federal regulators.
During a conference call last Wednesday, Kersten tipped off an invitation-only group of investors and brokers about Cel-Sci’s plan to issue a “major press release” later this week, possibly on Thursday, related to its cancer drug, called Multikine. The press release was to be issued simultaneously with a posting of Multikine clinical trial data on the government’s ClinicalTrials.gov website, Kersten said.
A participant provided STAT with access to the call and I heard Kersten’s entire presentation live. He also answered questions from listeners. The call was organized by an investor relations firm and lasted about 30 minutes.
“Our data are basically incomprehensible for most people,” Kersten told the participants, cautioning them that “only statisticians and physicians” would understand the complexities and significance of the Multikine data about to be posted on ClinicalTrials.gov.
Erik Gordon, a professor of business and law at the University of Michigan, said the information disclosed selectively by Kersten appears to be both material and non-public. If the participants invited to listen to Kersten are able to trade on the information, then Kersten and Cel-Sci could have violated Regulation Fair Disclosure, a rule implemented by the Securities and Exchange Commission in 2000 and designed to level the playing field for all investors.
“These comments [by Kersten] seem like waving a red flag in front of the SEC,” said Gordon.
The specific disclosures about Cel-Sci’s intent to issue a Multikine data press release or the posting of data on ClinicalTrials.gov this week have not been disseminated publicly.
Reached for comment, a Cel-Sci spokesperson said, “Go to the Clinicaltrials.gov website and all the information about the timing of the Multikine data is public. We are not responding to any other questions.”
During the call on Wednesday, Kersten repeated the claim that Multikine, a type of immunotherapy, extended the survival of certain patients with “low risk” head and neck cancer.
“Here’s the bottom line: When you see the data, just ask yourself, is this something I want for my wife, my child, a parent or a husband? Is this something I want for people who are dear to me? The answer is absolutely because there is no safety risk. It’s a three-week treatment that could have tremendous benefits. You won’t believe me until you see it,” Kersten said.
In his remarks, Kersten did not mention the Phase 3 study failed to achieve its main goal of demonstrating a survival benefit for all 920 patients enrolled — a fact Cel-Sci acknowledged last June 28 when the study results were announced. Kersten bases his claim on a post-hoc analysis that throws out 60% of the patients enrolled in the study.
At $3, Cel-Sci shares are down 87% since the Multikine study results were reported.
Kersten told the participants on last Wednesday’s call that the deteriorating market for biotech stocks overall was responsible for Cel-Sci’s decimated stock price.
“My gosh, one year ago it was a party. Stocks were flying. Things certainly have changed,” he said. “We were flying until November when we got our head chopped off. Our feet, our hands, everything.”
In fact, Cel-Sci stock in November was already down 50% from where it traded when the Multikine study results were announced.
Last August, Cel-Sci said publicly that it was planning to request a “pre-BLA” meeting with the agency to discuss the adequacy of the Multikine data to support an approval application. But then in December, the statement about requesting an FDA meeting was removed from its quarterly filing with the SEC, and no other update has been provided since.
A participant on Wednesday’s private call asked Kersten when the company would be filing the Multikine application with the FDA. Kersten did not answer directly.
“We are talking to the FDA. They don’t know anything about our drug because for 10 years we were blinded,” a reference to the decade it took the company to conduct the unsuccessful Phase 3 study. “Now, all the people at the FDA are new. There is not a single person there who had prior knowledge of Cel-Sci, so we are working through it with them,” he said.
One of the people that Cel-Sci hired to assist with the Multikine submission is a “lawyer who was a former assistant commissioner at the FDA in the oncology division,” Kersten said, adding “this person is like having a spy in the FDA for us.”
An FDA spokesperson, after being told of Kersten’s “spy” statement, responded: “We’re not going to comment on that.”
DATA OUT THIS WEEK!
Per GKs secret investor call, he is releasing a "MAJOR PR" this week.
https://www.statnews.com/2022/04/18/cel-scis-ceo-used-private-call-to-tip-off-select-investors-about-cancer-drug-update/?utm_campaign=rss
GO CVM
Cheers!
IM LONG 18K AGAIN
NEWS THIS WEEK PER DADDYS CONFERENCE CALL LAST WEEK!
"MAJOR PRESS RELEASE THIS WEEK"
GO CVM
KILLCVMSHORTS.com
CHEERS!
Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
Adam Fearstain SPEAKS
@tvdb
I’m retired now…so I have more time. Every day is the weekend!
Cheers!
HE HAS RISEN
No, not Jesus!
Geert Kersten TWEETED today!
Dr Talor and GK will be attending ASCO...not presenting.
Cheers!
He Has Risen!
Peace be with you and $2s this week
Cheers!
Happy Passover and Good Friday
Wishing all longs a wonderful holiday weekend
Unfortunately if no news in the coming weeks, this will be in the $2s
I remember posters blasting me when I said it would go to the $5s, then I said it would go to $4s and then I said $3s.
Looks like I’ve been right all along
I was swing trading this and telling you the trades while delusional posters watch their stock go from $25 to $3. Market cap is at $143M. Wow. It was nearly $1 Billion.
Wake up.
Peace be with you
Cheers!
You must be a newbie
Did u read the filing?
State Street sold millions of shares last q
13Gs are filed for many reasons
Cheers!
Im Buying The Dip Into The $2s
Cheers!
Indeed, I Do Have NWBO
It’s a lotto tix for me. I don’t follow the boards for that stock much but sounds like TLD by ASCO. They have a huge space and are presenting that Saturday in the Theater.
It has a long, history that makes CVM's look tame.
If it hits, $10s are in reach.
Regarding CVM, no position yet. It’s been a falling knife since last OpEx. Lost a few K on the last swing that didn’t pan out…but obviously I’ve still made a ton on this ticker. Looking at an RV to hitch up to the Wife's new Bronco. Empty nesters soon and we want to travel around America.
Geert luck to all
Cheers
Every Day is A Drop...
Who's buying this dip? Not me!
I'm in for $2s!
I remember when this was trading in the $20s...Woof!
For illustration purposes:
If I had 20K shares of CVM last year at $25, that was worth $500K. That same 20K is now worth $60K. That's a 440K hit...oh wait...only a "paper loss" the people will say! LOL
Cheers!
CONGRATS TO OTHERS THAT HAD $SSRA
Cheers!
$2s was my next target
Ill be a buyer in the $2s
Sad to see a stock lose so much value. From $41 to $3. WOOF!
Cheers
Confirmation Bias at its Finest
I guess CVM isn’t a “guaranteed winner” and that’s why State Street dumped??? NOT MY WORDS…
Two Things
13G Filed today By State Street. They reduced their position by 2.5M last quarter. Not great as they have been a big supporter. People with confirmation bias will spin this anyway they want…but why sell on the verge of good data/catalyst?
Short Interest declined a lot as of 3/31. Down 14% to 7.1M
Cheers
Soooo. Who can explain the 13G filing?
It’s not good.
13g just filed
Cheers
Hojake97
If 9+ months makes you sleep better, than thats fine
I retract my 12 months.
Its been "9+ months"
Cheers!
W_W
If, its published....What is your response if no publication is pending?
Cheers!
W_W
Why can other companies Chew Gum and Walk Too?
Hundreds of companies are attending and presenting at ASCO
Cheers!
Q
With all due respect, "hope" isnt an investment strategy
Furthermore, name 1 other instance where that example you offered actually occurred.
Seriously, why isnt CVM presenting at ASCO?
Why wont anyone provide any response?
Anyone? This is THE oncology conference of the YEAR and CVM is M.I.A.
Bueller!?
Cheers!